Pharmaceutical companies are moving away from all-inclusive, in-house operations and partnering with Contract Development and Manufacturing Organizations (CDMOs) for solvent-based solid-dose manufacturing. When researching CDMOs, important considerations about the organization’s capabilities and processes should be assessed. Although the considerations reviewed in this white paper are not intended to replace the quality assurance standards that companies have in place, they provide a guide to increase the confidence you have in your manufacturing partner.
